Pentagamavunon-1 PGV-1|cas:27060-70-4|西域试剂

Pentagamavunon-1 PGV-1,99.80%

产品编号：Bellancom-136477| CAS NO：27060-70-4| 分子式：C₂₃H₂₄O₃| 分子量：348.43

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-136477	￥600.00	杭州北京（现货）
Bellancom-136477	￥1000.00	杭州北京（现货）
Bellancom-136477	￥3000.00	杭州北京（现货）
Bellancom-136477	￥4500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Pentagamavunon-1 PGV-1

产品介绍

Pentagamavunon-1 (PGV-1) 是Curcumin 的类似物，具有口服活性，通过多个机制诱导凋亡信号，如抑制COX-2 和 VEGF。Pentagamavunon-1 (PGV-1) 可抑制 NF-κB 的激活。

生物活性

Pentagamavunon-1 (PGV-1), a Curcumin analog with oral activity, targets on several molecular mechanisms to induce apoptosis including inhibition of angiogenic factors cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF). PGV-1 inhibits NF-κB activation.

体外研究

Pentagamavunon-1 (PGV-1, 1, 2.5, 5, 7.5, 10, 15, and 20 µM) enhances cytotoxic effect of 5-FU on WiDr cells.
Pentagamavunon-1 (PGV-1, 1, 2.5, 5, and 10 µM) shows different effects on cell cycle progression and induces G2/M arrest.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay.

Cell Line:	Human colon carcinoma WiDr.
Concentration:	1, 2.5, 5, 7.5, 10, 15, and 20 µM.
Incubation Time:	6, 12, 24, and 48 hours.
Result:	Significantly enhanced the cytotoxicity of 5-FU on WiDr cells at various concentrations during 6, 12, 24, and 48 h incubation.

Cell Cycle Analysis.

Cell Line:	WiDr cells.
Concentration:	1, 2.5, 5, and 10 µM.
Incubation Time:	24 h.
Result:	The non-treated WiDr cells showed cell accumulation in G1, S, and G2/M phase about 50.85%, 36.11% and 13.04%, respectively.

体内研究
(In Vivo)

Pentagamavunon-1 (PGV-1, po, 20 mg/kg) exhibits significant anti-tumor activity in PDX model, without obvious toxicity.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Human cancer cells in a xenograf mouse model.
Dosage:	20mg/kg.
Administration:	P.O. every 2 days for 20 days.
Result:	Exhibited little decrease in body weight, nor a decrease in white and red blood cell counts in peripheral blood, nor any other efects in behavior and macroscopic appearance. Thus, PGV-1 was sufciently potent to suppress tumor formation in vivo, but exhibited little or no obvious adverse effects on the normal lineage of cells.

体内研究

Pentagamavunon-1 (PGV-1, po, 20 mg/kg) exhibits significant anti-tumor activity in PDX model, without obvious toxicity.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Human cancer cells in a xenograf mouse model.
Dosage:	20mg/kg.
Administration:	P.O. every 2 days for 20 days.
Result:	Exhibited little decrease in body weight, nor a decrease in white and red blood cell counts in peripheral blood, nor any other efects in behavior and macroscopic appearance. Thus, PGV-1 was sufciently potent to suppress tumor formation in vivo, but exhibited little or no obvious adverse effects on the normal lineage of cells.

体内研究

Pentagamavunon-1 (PGV-1, po, 20 mg/kg) exhibits significant anti-tumor activity in PDX model, without obvious toxicity.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Human cancer cells in a xenograf mouse model.
Dosage:	20mg/kg.
Administration:	P.O. every 2 days for 20 days.
Result:	Exhibited little decrease in body weight, nor a decrease in white and red blood cell counts in peripheral blood, nor any other efects in behavior and macroscopic appearance. Thus, PGV-1 was sufciently potent to suppress tumor formation in vivo, but exhibited little or no obvious adverse effects on the normal lineage of cells.

性状

Solid

溶解性数据

In Vitro:

DMSO : 50 mg/mL (143.50 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.8700 mL	14.3501 mL	28.7002 mL
5 mM	0.5740 mL	2.8700 mL	5.7400 mL
10 mM	0.2870 mL	1.4350 mL	2.8700 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 2.08 mg/mL (5.97 mM); Clear solution; Need ultrasonic

此方案可获得 2.08 mg/mL (5.97 mM) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: 2.08 mg/mL (5.97 mM); Clear solution; Need ultrasonic

此方案可获得 2.08 mg/mL (5.97 mM) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。